Wockhardt claims FDA issues with U.S. plant have been resolved

Wockhardt Chairman Habil Khorakiwala claims the company has satisfied FDA concerns laid out in a Form 483 by inspectors last year for a plant in Morton Grove, IL. The plant is key for Wockhardt after the FDA in 2013 banned two of its Indian plants for quality and data manipulation issues. Khorakiwala made the announcement while discussing the company's earnings. Story | More

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.